FICHIT

Je m'inscris

CROSSJECT

0/5 (0 note(s))
Note donnée : aucune
Paris
48
Develops needle-free injection systems for liquid medicines. The Company product ZENEO is tailored to deliver drugs intra-dermally, subcutaneously and intramuscularly.
CROSSJECT is developing an exciting pipeline of SUPERGENERICS or New Therapeutics Entities by combining well-known drug molecules with ZENEO, its proprietary needle-free injection system.
ZENEO® Methotrexate (rheumatoid arthritis): Bioequivalence study successfully completed during the second half of 2014. Currently in clinical stage.
ZENEO® Epinephrine (anaphylactic shock): benefits from a worldwide partnership agreement. Anaphylaxis is a serious allergic reaction that is rapid in onset and may cause death. Patients must receive an intramuscular injection of Epinephrine within minutes, as soon as the diagnostic is suspected. Currently in clinical stage.
ZENEO® Sumatriptan (acute migraine): Migraine is an intense, throbbing head pain. Migraines can cause some people to become nauseous and sensitive to light and sound. Triptans such as sumatriptan are effective and recommended for those with moderate to severe pain or those with milder symptoms. Currently in clinical stage.
MULLER Tim
www.crossject.com
ALCJ:FP

Fiche créée le 10/04/2016 par Guillaume   vue 16 fois.